Helius Medical (HSDT) Stock Forecast, Price Target & Predictions
HSDT Stock Forecast
Helius Medical stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
HSDT Analyst Ratings
According to 3 Wall Street analysts, Helius Medical's rating consensus is 'Buy'. The analyst rating breakdown for HSDT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 20, 2022 | Maxim Group | - | Buy | Initialise |
| Nov 17, 2022 | Zacks Investment Research | - | Buy | Upgrade |
| Aug 24, 2022 | Roth Capital | - | Buy | Initialise |
Helius Medical's last stock rating was published by Maxim Group on Dec 20, 2022. The company Initialise its HSDT rating from "null" to "Buy".
Helius Medical Financial Forecast
Helius Medical Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $143.00K | $256.00K | $111.00K | $282.00K | $196.00K | $119.00K | $190.00K | $258.00K | $109.00K | $71.00K | $84.00K | $191.00K | $131.00K | $133.00K | $207.00K | $152.00K | $150.00K | $518.00K | $677.00K |
| Avg Forecast | $441.00K | $318.00K | $299.00K | $248.00K | $268.00K | $150.00K | $150.00K | $110.00K | $249.67K | $345.00K | $188.33K | $275.00K | $262.33K | $167.50K | $360.00K | $160.00K | $100.00K | $84.50K | $95.00K | $93.50K | $170.00K | $100.00K | $100.00K | $300.00K | $200.00K | $300.00K | $300.00K | $150.00K |
| High Forecast | $441.00K | $318.00K | $299.00K | $248.00K | $268.00K | $150.00K | $150.00K | $110.00K | $249.67K | $345.00K | $188.33K | $275.00K | $262.33K | $167.50K | $360.00K | $160.00K | $100.00K | $84.50K | $95.00K | $93.50K | $170.00K | $100.00K | $100.00K | $300.00K | $200.00K | $300.00K | $300.00K | $150.00K |
| Low Forecast | $441.00K | $318.00K | $299.00K | $248.00K | $268.00K | $150.00K | $150.00K | $110.00K | $249.67K | $345.00K | $188.33K | $275.00K | $262.33K | $167.50K | $360.00K | $160.00K | $100.00K | $84.50K | $95.00K | $93.50K | $170.00K | $100.00K | $100.00K | $300.00K | $200.00K | $300.00K | $300.00K | $150.00K |
| # Analysts | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.41% | 1.36% | 0.40% | 1.07% | 1.17% | 0.33% | 1.19% | 2.58% | 1.29% | 0.75% | 0.90% | 1.12% | 1.31% | 1.33% | 0.69% | 0.76% | 0.50% | 1.73% | 4.51% |
Helius Medical's average Quarter revenue forecast for Dec 23 based on 2 analysts is $249.67K, with a low forecast of $249.67K, and a high forecast of $249.67K. HSDT's average Quarter revenue forecast represents a 74.59% increase compared to the company's last Quarter revenue of $143.00K (Sep 23).
Helius Medical EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | $-2.22M | $-3.22M | $-4.97M | $-321.00K | $-4.03M | $-2.98M | $-4.71M | $-4.03M | $-3.98M | $-6.29M | $-3.54M | $-3.37M | $-3.75M | $-3.91M | $-3.08M | $-5.76M | $-5.83M | $-11.40M | $-14.93M |
| Avg Forecast | $-441.00K | $-318.00K | $-299.00K | $-248.00K | $-268.00K | $-150.00K | $-150.00K | $-110.00K | $-249.67K | $-345.00K | $-188.33K | $-275.00K | $-262.33K | $-3.67M | $-360.00K | $-4.20M | $-100.00K | $-84.50K | $-4.21M | $-93.50K | $-170.00K | $-100.00K | $-100.00K | $-300.00K | $-200.00K | $-300.00K | $-300.00K | $-150.00K |
| High Forecast | $-441.00K | $-318.00K | $-299.00K | $-248.00K | $-268.00K | $-150.00K | $-150.00K | $-110.00K | $-249.67K | $-345.00K | $-188.33K | $-275.00K | $-262.33K | $-2.94M | $-360.00K | $-3.36M | $-100.00K | $-84.50K | $-3.37M | $-93.50K | $-170.00K | $-100.00K | $-100.00K | $-300.00K | $-200.00K | $-300.00K | $-300.00K | $-150.00K |
| Low Forecast | $-441.00K | $-318.00K | $-299.00K | $-248.00K | $-268.00K | $-150.00K | $-150.00K | $-110.00K | $-249.67K | $-345.00K | $-188.33K | $-275.00K | $-262.33K | $-4.41M | $-360.00K | $-5.04M | $-100.00K | $-84.50K | $-5.06M | $-93.50K | $-170.00K | $-100.00K | $-100.00K | $-300.00K | $-200.00K | $-300.00K | $-300.00K | $-150.00K |
| Surprise % | - | - | - | - | - | - | - | - | - | 6.43% | 17.09% | 18.09% | 1.22% | 1.10% | 8.27% | 1.12% | 40.27% | 47.15% | 1.49% | 37.86% | 19.80% | 37.46% | 39.08% | 10.26% | 28.79% | 19.44% | 38.01% | 99.55% |
undefined analysts predict HSDT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Helius Medical's previous annual EBITDA (undefined) of $NaN.
Helius Medical Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | $-3.66M | $-1.65M | $-1.08M | $-7.19M | $2.96M | $-4.57M | $-3.91M | $-4.10M | $-4.69M | $-5.98M | $-3.36M | $-2.53M | $-3.48M | $-3.36M | $-4.76M | $-4.80M | $-5.59M | $-186.00K | $1.32M |
| Avg Forecast | $-1.23M | $-1.28M | $-1.28M | $-2.19M | $-2.22M | $-2.67M | $-1.26M | $-12.69M | $-9.50M | $-15.11M | $-14.69M | $-13.85M | $-16.37M | $-3.73M | $-141.01M | $-4.27M | $-146.05M | $-220.33M | $-4.26M | $-190.11M | $-352.53M | $-396.60M | $-528.80M | $-705.06M | $-925.39M | $-969.46M | $-991.49M | $2.62M |
| High Forecast | $-1.23M | $-1.28M | $-1.28M | $-2.19M | $-2.22M | $-2.67M | $-1.26M | $-12.69M | $-9.50M | $-15.11M | $-14.69M | $-13.85M | $-16.37M | $-2.99M | $-141.01M | $-3.42M | $-146.05M | $-220.33M | $-3.41M | $-190.11M | $-352.53M | $-396.60M | $-528.80M | $-705.06M | $-925.39M | $-969.46M | $-991.49M | $3.15M |
| Low Forecast | $-1.23M | $-1.28M | $-1.28M | $-2.19M | $-2.22M | $-2.67M | $-1.26M | $-12.69M | $-9.50M | $-15.11M | $-14.69M | $-13.85M | $-16.37M | $-4.48M | $-141.01M | $-5.12M | $-146.05M | $-220.33M | $-5.11M | $-190.11M | $-352.53M | $-396.60M | $-528.80M | $-705.06M | $-925.39M | $-969.46M | $-991.49M | $2.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.24% | 0.11% | 0.08% | 0.44% | -0.79% | 0.03% | 0.92% | 0.03% | 0.02% | 1.40% | 0.02% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% | 0.51% |
Helius Medical's average Quarter net income forecast for Dec 22 is $-16.37M, with a range of $-16.37M to $-16.37M. HSDT's average Quarter net income forecast represents a -653.89% decrease compared to the company's last Quarter net income of $2.96M (Sep 22).
Helius Medical SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | $2.20M | $2.57M | $2.87M | $1.97M | $3.39M | $2.46M | $2.82M | $2.38M | $2.86M | $4.74M | $2.20M | $2.09M | $2.37M | $2.39M | $2.86M | $3.81M | $4.29M | $3.85M | $4.58M |
| Avg Forecast | $6.78M | $4.89M | $4.60M | $3.81M | $4.12M | $2.31M | $2.31M | $1.69M | $3.84M | $5.31M | $2.90M | $4.23M | $4.04M | $2.58M | $5.54M | $2.46M | $1.54M | $1.30M | $1.46M | $1.44M | $2.61M | $1.54M | $1.54M | $4.61M | $3.08M | $4.61M | $4.61M | $2.31M |
| High Forecast | $6.78M | $4.89M | $4.60M | $3.81M | $4.12M | $2.31M | $2.31M | $1.69M | $3.84M | $5.31M | $2.90M | $4.23M | $4.04M | $2.58M | $5.54M | $2.46M | $1.54M | $1.30M | $1.46M | $1.44M | $2.61M | $1.54M | $1.54M | $4.61M | $3.08M | $4.61M | $4.61M | $2.31M |
| Low Forecast | $6.78M | $4.89M | $4.60M | $3.81M | $4.12M | $2.31M | $2.31M | $1.69M | $3.84M | $5.31M | $2.90M | $4.23M | $4.04M | $2.58M | $5.54M | $2.46M | $1.54M | $1.30M | $1.46M | $1.44M | $2.61M | $1.54M | $1.54M | $4.61M | $3.08M | $4.61M | $4.61M | $2.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.41% | 0.89% | 0.68% | 0.49% | 1.32% | 0.44% | 1.15% | 1.54% | 2.20% | 3.25% | 1.53% | 0.80% | 1.54% | 1.56% | 0.62% | 1.24% | 0.93% | 0.83% | 1.99% |
Helius Medical's average Quarter SG&A projection for Dec 23 is $3.84M, based on 2 Wall Street analysts, with a range of $3.84M to $3.84M. The forecast indicates a 74.88% rise compared to HSDT last annual SG&A of $2.20M (Sep 23).
Helius Medical EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | $-5.49 | $-0.00 | $-0.04 | $-0.26 | $0.35 | $-1.16 | $-1.03 | $-1.31 | $-2.28 | $-2.42 | $-1.51 | $-1.12 | $-2.41 | $-2.32 | $-7.09 | $-6.05 | $-7.17 | $14.96 | $23.85 |
| Avg Forecast | $-0.49 | $-0.51 | $-0.51 | $-0.87 | $-0.88 | $-1.06 | $-0.50 | $-5.04 | $-3.77 | $-6.00 | $-5.83 | $-5.50 | $-6.50 | $-10.50 | $-56.00 | $-56.50 | $-58.00 | $-87.50 | $-80.75 | $-75.50 | $-140.00 | $-157.50 | $-210.00 | $-280.00 | $-367.50 | $-385.00 | $-393.75 | $-446.25 |
| High Forecast | $-0.49 | $-0.51 | $-0.51 | $-0.87 | $-0.88 | $-1.06 | $-0.50 | $-5.04 | $-3.77 | $-6.00 | $-5.83 | $-5.50 | $-6.50 | $-10.50 | $-56.00 | $-56.50 | $-58.00 | $-87.50 | $-80.75 | $-75.50 | $-140.00 | $-157.50 | $-210.00 | $-280.00 | $-367.50 | $-385.00 | $-393.75 | $-446.25 |
| Low Forecast | $-0.49 | $-0.51 | $-0.51 | $-0.87 | $-0.88 | $-1.06 | $-0.50 | $-5.04 | $-3.77 | $-6.00 | $-5.83 | $-5.50 | $-6.50 | $-10.50 | $-56.00 | $-56.50 | $-58.00 | $-87.50 | $-80.75 | $-75.50 | $-140.00 | $-157.50 | $-210.00 | $-280.00 | $-367.50 | $-385.00 | $-393.75 | $-446.25 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.92% | 0.00% | 0.01% | 0.04% | -0.03% | 0.02% | 0.02% | 0.02% | 0.03% | 0.03% | 0.02% | 0.01% | 0.02% | 0.01% | 0.03% | 0.02% | 0.02% | -0.04% | -0.05% |
According to 0 Wall Street analysts, Helius Medical's projected average Quarter EPS for Dec 22 is $-6.50, with a low estimate of $-6.50 and a high estimate of $-6.50. This represents a -1957.14% decrease compared to HSDT previous annual EPS of $0.35 (Sep 22).
Helius Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BJDX | Bluejay Diagnostics | $0.15 | $10.00 | 6566.67% | Buy |
| RPID | Rapid Micro Biosystems | $0.84 | $8.00 | 852.38% | Hold |
| AZYO | Elutia | $1.49 | $10.25 | 587.92% | Buy |
| HSDT | Helius Medical | $0.83 | $5.00 | 502.41% | Buy |
| SGHT | Sight Sciences | $6.95 | $10.33 | 48.63% | Hold |
| HSCS | Heart Test Laboratories | $3.04 | $3.00 | -1.32% | Buy |
HSDT Forecast FAQ
Is Helius Medical a good buy?
Yes, according to 3 Wall Street analysts, Helius Medical (HSDT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of HSDT's total ratings.
What are Helius Medical's analysts' financial forecasts?
Helius Medical's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $678K (high $678K, low $678K), average EBITDA is $-678K (high $-678K, low $-678K), average net income is $-18.835M (high $-18.835M, low $-18.835M), average SG&A $10.43M (high $10.43M, low $10.43M), and average EPS is $-7.48 (high $-7.48, low $-7.48). HSDT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.31M (high $1.31M, low $1.31M), average EBITDA is $-1.306M (high $-1.306M, low $-1.306M), average net income is $-5.993M (high $-5.993M, low $-5.993M), average SG&A $20.09M (high $20.09M, low $20.09M), and average EPS is $-2.38 (high $-2.38, low $-2.38).
Did the HSDT's actual financial results beat the analysts' financial forecasts?
Based on Helius Medical's last annual report (Dec 2023), the company's revenue was $644K, which missed the average analysts forecast of $1.06M by -39.13%. Apple's EBITDA was $-12.428M, beating the average prediction of $-1.058M by 1074.67%. The company's net income was $-8.85M, missing the average estimation of $-53.148M by -83.35%. Apple's SG&A was $9.27M, missing the average forecast of $16.27M by -43.03%. Lastly, the company's EPS was $-0.0146, missing the average prediction of $-21.107 by -99.93%. In terms of the last quarterly report (Sep 2023), Helius Medical's revenue was $143K, missing the average analysts' forecast of $345K by -58.55%. The company's EBITDA was $-2.218M, beating the average prediction of $-345K by 542.90%. Helius Medical's net income was $-3.663M, missing the average estimation of $-15.108M by -75.76%. The company's SG&A was $2.2M, missing the average forecast of $5.31M by -58.62%. Lastly, the company's EPS was $-5.49, missing the average prediction of $-6 by -8.50%